66
Views
4
CrossRef citations to date
0
Altmetric
Original

Postremission therapy for acute myeloid leukemia in the first remission

, , , , , , , , , , , & show all
Pages 937-943 | Received 27 Jun 2006, Accepted 13 Jan 2007, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yi WANG, Aya NAKAJIMA, Kakushi HOSOKAWA, Azamjon B. SOLIEV, Issey OSAKA, Ryuichi ARAKAWA & Keiichi ENOMOTO. (2012) Cytotoxic Prodigiosin Family Pigments from Pseudoalteromonas sp. 1020R Isolated from the Pacific Coast of Japan. Bioscience, Biotechnology, and Biochemistry 76:6, pages 1229-1232.
Read now

Articles from other publishers (3)

Silvia Park, Hangseok Choi, Hee Je Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Sung-Hyun Kim, Yeung-Chul Mun, Chul Won Jung & Dennis Kim. (2018) Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. Annals of Hematology 97:6, pages 955-965.
Crossref
Hee Kyung Ahn, Jun Ho Jang, Kihyun Kim, Hee‐Jin Kim, Sun‐Hee Kim, Chul Won Jung & Dong Hwan (Dennis) Kim. (2011) Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. American Journal of Hematology 87:1, pages 37-41.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:1, pages 46-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.